Press "Enter" to skip to content

ASCO 2019: Pembrolizumab plus Docetaxel and Prednisone in Abiraterone or Enzalutamide-Pretreated Patients with Metastatic Castrate Resistant Prostate Cancer: Cohort B of the Phase 1b/2 KEYNOTE-365 study – Medical Oncologist Perspective – UroToday

admin 0

ASCO 2019: Pembrolizumab plus Docetaxel and Prednisone in Abiraterone or Enzalutamide-Pretreated Patients with Metastatic Castrate Resistant Prostate Cancer: Cohort B of the Phase 1b/2 KEYNOTE-365 study – Medical Oncologist Perspective  UroToday

ASCO 2019 KEYNOTE 365, a 4-cohort study evaluating efficacy of pembrolizumab in combination with Olaparib, Docetaxel, Enzalutamide or Abiraterone, …

“prostate cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *